Damon Race: Pleased to Share GeneVentiv’s Scientific Debut at ASGCT 2026
Damon Race, President and CEO of GeneVentiv Therapeutics, Inc., shared on LinkedIn:
”We’re pleased to share GeneVentiv’s scientific debut at ASGCT 2026.
Our CSO, Paris Margaritis, DPhil, is presenting our work on a next-generation AAV8.FVa construct, advancing a differentiated approach to restoring thrombin generation in hemophilia A patients with or without inhibitors through native hepatic expression of a regulated coagulation cofactor.
The technology presented here forms part of GeneVentiv’s growing IP portfolio.
It’s exciting to reflect on this work as the foundation for our program, which has advanced to studies in hemophilia A canines.
We look forward to sharing additional data as development progresses.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering